S&P 500   3,970.99
DOW   32,237.53
QQQ   310.89
Biden's moves on Alaska drilling, TikTok test young voters
BREAKING: Tiny biotech successfully treats blindness (Ad)
Ruling halts oil exports from Iraq's Kurdish area via Turkey
Finnish leadership condemns attack on veteran lawmaker
Fed's Shocking New Plan to Control Your Money (Ad)
Venezuela: 21 officials, businessmen arrested in oil scheme
Canada pledges Great Lakes funding after Trudeau-Biden talks
Fed's Shocking New Plan to Control Your Money (Ad)
Challenger wins close race to lead United Auto Workers union
Idaho governor signs firing squad execution bill into law
S&P 500   3,970.99
DOW   32,237.53
QQQ   310.89
Biden's moves on Alaska drilling, TikTok test young voters
BREAKING: Tiny biotech successfully treats blindness (Ad)
Ruling halts oil exports from Iraq's Kurdish area via Turkey
Finnish leadership condemns attack on veteran lawmaker
Fed's Shocking New Plan to Control Your Money (Ad)
Venezuela: 21 officials, businessmen arrested in oil scheme
Canada pledges Great Lakes funding after Trudeau-Biden talks
Fed's Shocking New Plan to Control Your Money (Ad)
Challenger wins close race to lead United Auto Workers union
Idaho governor signs firing squad execution bill into law
S&P 500   3,970.99
DOW   32,237.53
QQQ   310.89
Biden's moves on Alaska drilling, TikTok test young voters
BREAKING: Tiny biotech successfully treats blindness (Ad)
Ruling halts oil exports from Iraq's Kurdish area via Turkey
Finnish leadership condemns attack on veteran lawmaker
Fed's Shocking New Plan to Control Your Money (Ad)
Venezuela: 21 officials, businessmen arrested in oil scheme
Canada pledges Great Lakes funding after Trudeau-Biden talks
Fed's Shocking New Plan to Control Your Money (Ad)
Challenger wins close race to lead United Auto Workers union
Idaho governor signs firing squad execution bill into law
S&P 500   3,970.99
DOW   32,237.53
QQQ   310.89
Biden's moves on Alaska drilling, TikTok test young voters
BREAKING: Tiny biotech successfully treats blindness (Ad)
Ruling halts oil exports from Iraq's Kurdish area via Turkey
Finnish leadership condemns attack on veteran lawmaker
Fed's Shocking New Plan to Control Your Money (Ad)
Venezuela: 21 officials, businessmen arrested in oil scheme
Canada pledges Great Lakes funding after Trudeau-Biden talks
Fed's Shocking New Plan to Control Your Money (Ad)
Challenger wins close race to lead United Auto Workers union
Idaho governor signs firing squad execution bill into law

Kiniksa Pharmaceuticals - KNSA Stock Forecast, Price & News

$11.41
+0.18 (+1.60%)
(As of 03/24/2023 12:00 AM ET)
Add
Compare
Today's Range
$10.76
$11.47
50-Day Range
$11.11
$14.55
52-Week Range
$7.36
$17.19
Volume
232,554 shs
Average Volume
481,626 shs
Market Capitalization
$795.85 million
P/E Ratio
4.41
Dividend Yield
N/A
Price Target
$20.00

Kiniksa Pharmaceuticals MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
75.3% Upside
$20.00 Price Target
Short Interest
Healthy
3.90% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
1.80mentions of Kiniksa Pharmaceuticals in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.59) to ($0.10) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.61 out of 5 stars

Medical Sector

103rd out of 1,005 stocks

Pharmaceutical Preparations Industry

39th out of 486 stocks


KNSA stock logo

About Kiniksa Pharmaceuticals (NASDAQ:KNSA) Stock

Kiniksa Pharmaceuticals Ltd. is a biopharmaceutical company, which engages in discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need. Its products include Rilonacept, Mavrilimumab, Vixarelimab, and KPL-404. The company was founded by Sanj K. Patel, Stephen Frank Mahoney, Krisha S. Mahoney, Thomas W. Beetham, Christopher Heberlig, Carsten Boess, Rasmus Holm-Jorgensen, Gregory Alex Grabowksi, Aaron Isadore Young, Eben P. Tessari, Jennifer Lynne Mason and Mickenzie Elizabeth Gallagher in July 2015 and is headquartered in Lexington, MA.

Receive KNSA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Kiniksa Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

KNSA Stock News Headlines

The Top 7 Growth Stocks in Biotech
Biden To Unleash "Choke Point" Operation On America?
Biden's disturbing new government program may be worse than Obama's. You are at risk for having your bank account frozen. A former bank regulator is blowing the whistle on Biden's frightening plan to take over your money. Discover the immediate steps you need to take now.
Earnings Scheduled For February 28, 2023
Biden To Unleash "Choke Point" Operation On America?
Biden's disturbing new government program may be worse than Obama's. You are at risk for having your bank account frozen. A former bank regulator is blowing the whistle on Biden's frightening plan to take over your money. Discover the immediate steps you need to take now.
KNSA Kiniksa Pharmaceuticals, Ltd.
Recap: Kiniksa Pharmaceuticals Q3 Earnings
See More Headlines
Receive KNSA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Kiniksa Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

KNSA Company Calendar

Last Earnings
11/01/2021
Today
3/26/2023
Next Earnings (Estimated)
5/02/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:KNSA
Fax
N/A
Employees
215
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$20.00
High Stock Price Forecast
$20.00
Low Stock Price Forecast
$20.00
Forecasted Upside/Downside
+75.3%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Net Income
$183.36 million
Pretax Margin
5.01%

Debt

Sales & Book Value

Annual Sales
$220.18 million
Cash Flow
$2.74 per share
Book Value
$5.68 per share

Miscellaneous

Free Float
31,689,000
Market Cap
$795.85 million
Optionable
Not Optionable
Beta
-0.07

Key Executives

  • Sanj K. Patel
    Chairman & Chief Executive Officer
  • Eben P. Tessari
    Chief Operating Officer & Senior Vice President
  • Mark Ragosa
    Chief Financial Officer & Senior Vice President
  • John F. Paolini
    Chief Medical Officer & Senior Vice President
  • Chad Morin
    Chief Compliance Officer & Vice President













KNSA Stock - Frequently Asked Questions

Should I buy or sell Kiniksa Pharmaceuticals stock right now?

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Kiniksa Pharmaceuticals in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" KNSA shares.
View KNSA analyst ratings
or view top-rated stocks.

What is Kiniksa Pharmaceuticals' stock price forecast for 2023?

1 equities research analysts have issued 12 month target prices for Kiniksa Pharmaceuticals' stock. Their KNSA share price forecasts range from $20.00 to $20.00. On average, they predict the company's stock price to reach $20.00 in the next year. This suggests a possible upside of 75.3% from the stock's current price.
View analysts price targets for KNSA
or view top-rated stocks among Wall Street analysts.

How have KNSA shares performed in 2023?

Kiniksa Pharmaceuticals' stock was trading at $14.98 at the beginning of 2023. Since then, KNSA stock has decreased by 23.8% and is now trading at $11.41.
View the best growth stocks for 2023 here
.

When is Kiniksa Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 2nd 2023.
View our KNSA earnings forecast
.

How were Kiniksa Pharmaceuticals' earnings last quarter?

Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) issued its quarterly earnings data on Monday, November, 1st. The company reported ($0.44) earnings per share for the quarter, topping analysts' consensus estimates of ($0.65) by $0.21. The company had revenue of $12.10 million for the quarter, compared to analysts' expectations of $9.92 million. Kiniksa Pharmaceuticals had a net margin of 83.28% and a trailing twelve-month return on equity of 2.18%.

What is Sanj K. Patel's approval rating as Kiniksa Pharmaceuticals' CEO?

1 employees have rated Kiniksa Pharmaceuticals Chief Executive Officer Sanj K. Patel on Glassdoor.com. Sanj K. Patel has an approval rating of 100% among the company's employees. This puts Sanj K. Patel in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Kiniksa Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Kiniksa Pharmaceuticals investors own include Exelixis (EXEL), CRISPR Therapeutics (CRSP), Pfizer (PFE), VBI Vaccines (VBIV), SCYNEXIS (SCYX), Sorrento Therapeutics (SRNE), AbbVie (ABBV), Dicerna Pharmaceuticals (DRNA), Vaxart (VXRT) and Advanced Micro Devices (AMD).

When did Kiniksa Pharmaceuticals IPO?

(KNSA) raised $126 million in an IPO on Thursday, May 24th 2018. The company issued 7,000,000 shares at $17.00-$19.00 per share. Goldman Sachs and J.P. Morgan served as the underwriters for the IPO and JMP Securities and Wedbush PacGrow were co-managers.

What is Kiniksa Pharmaceuticals' stock symbol?

Kiniksa Pharmaceuticals trades on the NASDAQ under the ticker symbol "KNSA."

Who are Kiniksa Pharmaceuticals' major shareholders?

Kiniksa Pharmaceuticals' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Millennium Management LLC (1.11%), ArrowMark Colorado Holdings LLC (1.03%), Rice Hall James & Associates LLC (1.00%), Morgan Stanley (0.87%), Geode Capital Management LLC (0.78%) and Granahan Investment Management LLC (0.73%). Insiders that own company stock include Barry D Quart, Sanj K Patel and Thomas W Beetham.
View institutional ownership trends
.

How do I buy shares of Kiniksa Pharmaceuticals?

Shares of KNSA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Kiniksa Pharmaceuticals' stock price today?

One share of KNSA stock can currently be purchased for approximately $11.41.

How much money does Kiniksa Pharmaceuticals make?

Kiniksa Pharmaceuticals (NASDAQ:KNSA) has a market capitalization of $795.85 million and generates $220.18 million in revenue each year. The company earns $183.36 million in net income (profit) each year or $2.59 on an earnings per share basis.

How many employees does Kiniksa Pharmaceuticals have?

The company employs 215 workers across the globe.

How can I contact Kiniksa Pharmaceuticals?

Kiniksa Pharmaceuticals' mailing address is CLARENDON HOUSE 2 CHURCH STREET, HAMILTON D0, HM11. The official website for the company is www.kiniksa.com. The company can be reached via phone at (781) 431-9100 or via email at ir@kiniksa.com.

This page (NASDAQ:KNSA) was last updated on 3/26/2023 by MarketBeat.com Staff